Common Contracts
22 similar Employment Agreement contracts by Gritstone Oncology, Inc., IDEAYA Biosciences, Inc., Annexon, Inc., others
INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 19th, 2022 • Inhibitor Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (the “Agreement”), entered into as of December 13, 2022 (the “Effective Date”), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”) and James A. McNulty (“Executive” and, together with the Company, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New Jersey
This Employment Agreement (the “Agreement”), is entered into effective as of December 7, 2020 (the “Effective Date”), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the “Company”) and Suba Krishnan (“Executive” and, together with the Company, the “Parties”).
SEELOS THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 10th, 2022 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Employment Agreement (this “Agreement”), entered into as of January 10, 2022 (the “Agreement Date”), is made by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Raj Mehra, Ph.D. (“Executive” and together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the date the “Term” under that certain March 20, 2019 Employment Agreement between the Company and the Executive otherwise would expire (such date, the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is entered into effective as of July 1, 2020 (the “Effective Date”), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the “Company”) and John Lewicki, Ph.D. (“Executive” and, together with the Company, the “Parties”).
ANNEXON, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 20th, 2020 • Annexon, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is made and entered into by and between Annexon, Inc., a Delaware corporation (the “Company”) and Michael Overdorf (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of July 2, 2020 (“Offer Letter”).
ANNEXON, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2020 • Annexon, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is made and entered into by and between Annexon, Inc., a Delaware corporation (the “Company”) and Douglas E. Love, Esq. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of December 11, 2014 (“Offer Letter”).
ANNEXON, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2020 • Annexon, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is made and entered into by and between Annexon, Inc., a Delaware corporation (the “Company”) and Ted Yednock (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of December 11, 2014 (“Offer Letter”).
ANNEXON, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2020 • Annexon, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is made and entered into by and between Annexon, Inc., a Delaware corporation (the “Company”) and Sanjay Keswani (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of April 9, 2019 (“Offer Letter”).
ANNEXON, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2020 • Annexon, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is made and entered into by and between Annexon, Inc., a Delaware corporation (the “Company”) and Jennifer Lew (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of April 29, 2019 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 9, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Paul A. Stone (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 13, 2018 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 10, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Mark R. Lackner, Ph.D. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 1, 2018 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 9, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Julie Hambleton, M.D. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 20, 2018 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 10, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Michael Dillon, Ph.D. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 13, 2016 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 13th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 9, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Yujiro Hata (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 29, 2015 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. FORM OF EXECUTIVE EMPLOYMENT AGREEMENTEmployment Agreement • May 13th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May [ ], 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and [ ] (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 1, 2018 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Roman Yelensky (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of September 22, 2015 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Raphaël Rousseau (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of November 15, 2016 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Erin Jones (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of March 23, 2016 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018(the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Andrew Allen (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 7, 2015 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Jean-Marc Bellemin (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of December 16, 2017 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Matthew Hawryluk (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 8, 2015 (“Offer Letter”).
UNITY BIOTECHNOLOGY, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 5th, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”), entered into as of January 29, 2018 (the “Effective Date”), is made by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”) and Keith R. Leonard, Jr. (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employment Agreement by and between Executive and the Company dated as of October 26, 2016 (the “Prior Agreement”).
